Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Mizuho

Evaluate

October 30, 2017

Ectrims 2017 – Ozanimod cannot chase away Celgene’s woes

October 20, 2017

Celgene gutted as mongersen heads for the scrapheap

Article image
Vantage logo
October 09, 2017

PCSK9 wrangle opens can of worms for antibody makers

Regeneron and Sanofi's PCSK9 court win could reverberate across the whole monoclonal antibody space.

Vantage logo
October 02, 2017

US open access plan backfires

Vantage logo
August 25, 2017

Snippet roundup: Adamas and Alexion score approvals and Amgen gets the price right

Vantage logo
August 04, 2017

Upcoming events – FDA decision for Adamas in Parkinson’s dyskinesia and growth data for Versartis

Vantage logo
July 21, 2017

Data put a dent in Ironwood’s expansion plans

Vantage logo
June 14, 2017

No near-term cure for Repatha and Praluent discontents

Vantage logo
March 29, 2017

Roche prices Ocrevus for maximum disruption

Vantage logo
March 09, 2017

Event – FDA panel to re-examine Opana ER

Vantage logo
March 06, 2017

ACC – Repatha’s next challenge is expectations

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up